PrecisionLife identifies first detailed genetic risk factors for long COVID

Long COVID is a debilitating chronic condition that has affected over 100 million people globally

Dupixent is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Sumitomo Pharma America launches as new combined organization

SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets

Moderna announces regulatory submissions for its RSV vaccine

The company has submitted marketing authorization applications for mRNA-1345 with the European Medicines Agency (EMA), Swissmedic in Switzerland, and the Therapeutic Goods Administration (TGA) in Australia

Novavax's Nuvaxovid receives full marketing authorization in the EU

Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU

Sirolimus drug coated balloons is an alternative to stents, say Cardiologists

Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective

PrecisionLife Licenses University of Oxford data to discover personalised treatments for endometriosis patients

PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments

Merck to expand reagent production capacity in China

The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons

Boehringer Ingelheim and Zealand Pharma Phase II trial with survodutide shows nearly 19% weight loss in people with obesity

Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite

Oncodesign Services announce access to ImaginAb’s CD8 ImmunoPET technology

Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement